HUP0004976A2 - Pharmaceutical compositions comprising copper(1) oxide and/or elemental copper for the treatment and prevention of mycosis and other infections, process for the preparation of the active component - Google Patents
Pharmaceutical compositions comprising copper(1) oxide and/or elemental copper for the treatment and prevention of mycosis and other infections, process for the preparation of the active componentInfo
- Publication number
- HUP0004976A2 HUP0004976A2 HU0004976A HUP0004976A HUP0004976A2 HU P0004976 A2 HUP0004976 A2 HU P0004976A2 HU 0004976 A HU0004976 A HU 0004976A HU P0004976 A HUP0004976 A HU P0004976A HU P0004976 A2 HUP0004976 A2 HU P0004976A2
- Authority
- HU
- Hungary
- Prior art keywords
- copper
- oxide
- prevention
- treatment
- infections
- Prior art date
Links
- 239000010949 copper Substances 0.000 title abstract 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title abstract 5
- 229910052802 copper Inorganic materials 0.000 title abstract 5
- 206010017533 Fungal infection Diseases 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 title 1
- 208000024386 fungal infectious disease Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 abstract 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 208000031888 Mycoses Diseases 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 230000000843 anti-fungal effect Effects 0.000 abstract 2
- 229940121375 antifungal agent Drugs 0.000 abstract 2
- 229960005070 ascorbic acid Drugs 0.000 abstract 2
- 235000010323 ascorbic acid Nutrition 0.000 abstract 2
- 239000011668 ascorbic acid Substances 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 239000003638 chemical reducing agent Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 239000011573 trace mineral Substances 0.000 abstract 2
- 235000013619 trace mineral Nutrition 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 238000011946 reduction process Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Antifungal pharmaceutical preparation contains copper(I) oxide and/or copper, and it is suitable for prevention and treatment of granulating and other fungal infections, some bacterial and viral infections. The copper(I) oxide and/or copper preparations may also contain essential trace elements and reducing agents, especially ascorbic acid. Antifungal pharmaceutical preparation contains copper(I) oxide and/or copper, and it is suitable for prevention and treatment of granulating and other fungal infections, some bacterial and viral infections. The copper(I) oxide and/or copper preparations may also contain essential trace elements and reducing agents, especially ascorbic acid. The copper(I)-oxide is prepared in a large crystal form, by a reduction process using sugar in an aqueous solution of copper(II) oxide-hydrogen-carbonate-halogen complex of formula [Cu(HCO3)X3]2>+> where X = F, Cl, Br, at 90-100 [deg]C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0004976A HUP0004976A2 (en) | 2000-12-19 | 2000-12-19 | Pharmaceutical compositions comprising copper(1) oxide and/or elemental copper for the treatment and prevention of mycosis and other infections, process for the preparation of the active component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0004976A HUP0004976A2 (en) | 2000-12-19 | 2000-12-19 | Pharmaceutical compositions comprising copper(1) oxide and/or elemental copper for the treatment and prevention of mycosis and other infections, process for the preparation of the active component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HU0004976D0 HU0004976D0 (en) | 2001-02-28 |
| HUP0004976A2 true HUP0004976A2 (en) | 2002-10-28 |
Family
ID=89978869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0004976A HUP0004976A2 (en) | 2000-12-19 | 2000-12-19 | Pharmaceutical compositions comprising copper(1) oxide and/or elemental copper for the treatment and prevention of mycosis and other infections, process for the preparation of the active component |
Country Status (1)
| Country | Link |
|---|---|
| HU (1) | HUP0004976A2 (en) |
-
2000
- 2000-12-19 HU HU0004976A patent/HUP0004976A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU0004976D0 (en) | 2001-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0943331A3 (en) | Formulations containing oxaliplatin | |
| WO2003004098A8 (en) | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent | |
| CA2468916A1 (en) | A stable oxaliplatin solution formulation | |
| CA2366702A1 (en) | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents | |
| ZA200501715B (en) | Solution for ungual application | |
| CA2003190A1 (en) | Pharmaceutical compositions containing n-(3,4-dimethoxycinnamoyl) anthranilic acid | |
| WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| CA2333601A1 (en) | Surfactant for use in external preparations for skin and external preparation for skin containing the same | |
| CA2547990A1 (en) | Pharmaceutical compositions and methods for insulin treatment | |
| IL172868A0 (en) | Process for preparing an alpha-1-antitrypsin solution | |
| AU2001262011A1 (en) | A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component | |
| GB2383041A (en) | Process for the preparation of gabapentin | |
| WO2002015933A3 (en) | Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser | |
| CA2347447A1 (en) | Buffered compositions for dialysis | |
| HUP0004976A2 (en) | Pharmaceutical compositions comprising copper(1) oxide and/or elemental copper for the treatment and prevention of mycosis and other infections, process for the preparation of the active component | |
| WO2004095921A3 (en) | Sporicidal composition | |
| WO2002043510A3 (en) | Methods of stabilizing fruit-concentrate powders | |
| WO2002055022A3 (en) | Active metabolite of antifungal compound | |
| AU2001285944A1 (en) | Fungicidal agent containing n-chlorotaurine and use thereof | |
| CA2338988A1 (en) | Aqueous growth-regulating compositions | |
| IL144827A0 (en) | Soluble double metal salts of hydroxycitric acid, processes for the preparation thereof and beverages containing the same | |
| CA2233331A1 (en) | Use of sphingosylphosphorylcholine as a wound-healing agent | |
| CA2387600A1 (en) | Novel fusidic acid derivatives | |
| WO1998023574A8 (en) | Asiatic acid derivatives and medicines for treating wounds, which contains the same | |
| WO2004058141A3 (en) | An agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component |